Vericel

American biopharmaceutical company

For the gymnyst, see Cassy Vericel.

Vericel CorporationFormerly| Aastrom Biosciences, Inc.

|

Company type| Public

Traded as

| Nasdaq: VCEL
Russell 2000 component
S&P 600 component
Industry| Biotechnology
Founded| 1989; 36 years ago (1989) in Ann Arbor, Michigan, United States
Headquarters|

Cambridge, Massachusetts

United States

Number of locations

| 2

Key people

* Nick Colangelo (CEO)
* Daniel Orlando (COO)
* Gerard Michel (CFO)

Products|

* MACI
* Epicel
* Carticel

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.[1]

In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011.[1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.[1]

In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.[1]

## References

[edit]

1. ^ a b c d Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template